Conversion therapy in advanced perihilar cholangiocarcinoma based on patient-derived organoids: A case report

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-1)

Sum=23

Oct 15, 2024 (publication date) through Sep 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4274-4280
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4274

Table 1 Changes of tumor markers at different time points during treatment

Indicators	AFP (ng/mL)	CA19-9 (U/mL)	CEA (ng/mL)	CA125 (U/mL)	CA15-3 (U/mL)
On admission	2.23	136.13	16.68	1000	112
After treatment for 2 weeks	5.86	127.24	20.25	1210	122
After organoid-based treatment for 4 cycles	2.12	43.84	4.21	16	12.2
First year after surgery	2.3	39.67	2.62	21.2	10.6

AFP: Alpha fetal protein; CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen.

Citation: He YG, Zhang LY, Li J, Wang Z, Zhao CY, Zheng L, Huang XB. Conversion therapy in advanced perihilar cholangiocarcinoma based on patient-derived organoids: A case report. World J Gastrointest Oncol 2024; 16(10): 4274-4280
URL: https://www.wjgnet.com/1948-5204/full/v16/i10/4274.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i10.4274